Nephrotic Syndrome
📧 Sign up to get email alerts when something new happens for Nephrotic Syndrome.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-07-14EMA Authorised: Qaialdo (spironolactone) — Lipomed GmbH
EMA has authorized Qaialdo, a spironolactone product by Lipomed GmbH, for several conditions including edema, heart failure, liver cirrhosis…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Effects of Meal Macronutrients on Postprandial Lipids [Phase 2]
Phase 2 clinical trial update by the National Institute of Diabetes and Digestive and Kidney Diseases evaluating how meal macronutrients inf…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Immune System Related Kidney Disease
A National Institute of Diabetes and Digestive and Kidney Diseases-sponsored clinical trial investigating immune system-related kidney disea…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy [Phase 2]
A Phase 2 trial evaluating rituximab plus cyclosporine for idiopathic membranous nephropathy is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: SLIT ABS: Study on Patients With Autoimmune Podocytopathy [NA]
This clinical trial update indicates the SLIT ABS study for autoimmune podocytopathy is currently recruiting, sponsored by Meyer Children's …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Multitarget Strategy for Primary Podocytopathies [NA]
Clinical trial update on a multitarget strategy for primary podocytopathies in nephrotic syndrome. The study is currently recruiting.
-
EMA approval · 2026-03-24EMA Authorised: Qaialdo (spironolactone) — Lipomed GmbH
Qaialdo is a spironolactone product by Lipomed GmbH that has been authorized in the EU. Indications include edema, heart failure, liver cirr…
-
CLINICAL_TRIALS research · 2026-03-06Clinical Trial Update: A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria [Phase 2]
A Phase 2 clinical trial is evaluating AP1189 in patients with idiopathic membranous nephropathy who have nephrotic syndrome or severe prote…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: A Study of Anti-CD38 Monoclonal Antibody (SG301) Subcutaneous Injection in Children With Nephrotic Syndrome With Frequent Relapses or Steroid Dependence [Phase 2]
Phase 2 trial evaluating SG301, a CD38-targeting monoclonal antibody, given subcutaneously in children with nephrotic syndrome who have freq…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Belimumab With Rituximab for Primary Membranous Nephropathy [Phase 2]
Phase 2 clinical trial evaluating the combination of belimumab with rituximab for primary membranous nephropathy is currently recruiting.
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: Study of Ripertamab in Children With Frequent Relapses or Steroid-Dependent Nephrotic Syndrome [NA]
A clinical trial update for ripertamab in children with frequent relapses or steroid-dependent nephrotic syndrome; the study is not yet recr…
-
FDA approval · 2026-02-05FDA Approved: BUMETANIDE — Original Application (Novadoz Pharmaceuticals LLC)
FDA approves the original application for bumetanide (generic) from Novadoz Pharmaceuticals LLC, a loop diuretic indicated for edema associa…
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease [Phase 1]
Phase 1 clinical trial update for a CAR T-cell therapy targeting CD19 and BCMA in autoimmune conditions, with recruiting status and potentia…
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome [Phase 2, Phase 3]
Clinical trial update on the use of SGLT2 inhibitors for adult primary nephrotic syndrome, covering Phase 2 and Phase 3, sponsored by Mansou…
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: Atacicept in Multiple Glomerular Diseases [Phase 2]
Phase 2 clinical trial evaluating atacicept in multiple glomerular diseases is currently recruiting, including primary membranous nephropath…
-
FDA approval · 2026-01-08FDA Approved: FUROSEMIDE — Original Application (Micro Labs Limited)
FDA approved the original application for furosemide from Micro Labs Limited.
-
FDA approval · 2026-01-07FDA Approved: METOLAZONE — Supplemental Application (Method Pharmaceuticals, LLC)
The FDA approved a supplemental application for METOLAZONE submitted by Method Pharmaceuticals, LLC.
-
CLINICAL_TRIALS trial_result · 2026-01-06Clinical Trial Update: Efficacy And Safety Of Azithromycin To Achieve Remissionin In Children With Steroid Sensitive Nephrotic Syndrome [Phase 1]
Phase 1 trial evaluating the safety and potential efficacy of azithromycin to achieve remission in children with steroid-sensitive nephrotic…
-
FDA approval · 2025-12-22FDA Approved: FUROSCIX — Supplemental Application (scPharmaceuticals Inc.)
The FDA approved a supplemental application for FUROSCIX (furosemide injection 80 mg/10 mL) from scPharmaceuticals Inc.
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
This clinical trial update describes an interview study of adult and pediatric patients with swelling due to nephrotic syndrome and of paren…
-
CLINICAL_TRIALS research · 2025-12-05Clinical Trial Update: Dupilumab Therapy in Nephrotic Syndrome in Children [Phase 2]
The document describes a Phase 2 clinical trial evaluating dupilumab for nephrotic syndrome in children, including steroid-dependent nephrot…
-
FDA approval · 2025-11-14FDA Approved: ALDACTONE — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approves a supplemental application for Aldactone (spironolactone) from Pfizer Laboratories Div Pfizer Inc.
-
FDA approval · 2025-10-07FDA Approved: LASIX ONYU — Original Application (SQ Innovation, Inc.)
FDA approves LASIX ONYU for the same active ingredient furosemide under an Original Application by SQ Innovation, Inc. The product is now au…
-
CLINICAL_TRIALS research · 2025-10-03Clinical Trial Update: The Role of Vitamin K2 in Preventing Glucocorticoid-Induced Bone Loss in Children With Nephrotic Syndrome [NA]
A clinical trial sponsored by Ain Shams University is evaluating whether Vitamin K2 can prevent glucocorticoid-induced bone loss in children…
-
CLINICAL_TRIALS trial_result · 2025-10-01Clinical Trial Update: Rituximab and Targeted Nursing for Pediatric Nephrotic Syndrome [NA]
The clinical trial evaluating rituximab plus targeted nursing for pediatric nephrotic syndrome has completed.